Download Full Text (1.1 MB)


Background: Poly (lactic-co-glycolic acid) (PLGA) and polyethylene glycol (PEG) are polymers approved by the United States’ Food and Drug Administration. Drugs for various medical treatments have been encapsulated in PLGA-PEG nanoparticles for targeted delivery and reduction of unwanted side effects.

Methods: A flow synthesis method for PLGA-PEG nanoparticles containing FoxO1 inhibitors and adipose vasculature targeting agents was developed. A set of nanoparticles including PLGA and PLGA-PEG-P3 unloaded and drug loaded were generated. The particles were characterized by DLS, fluorescence spectroscopy, TEM, and dialysis. Endotoxin levels were measured using the LAL chromogenic assay. Our approach was compared to over 270 research articles using information extraction tools.

Results: Nanoparticle hydrodynamic diameters ranged from 142.4 ±0.4 d.nm to 208.7 ±3.6 d.nm while the polydispersity index was less than 0.500 for all samples (0.057 ±0.021 to 0.369 ±0.038). Zeta potentials were all negative ranging from -4.33 mV to -13.4 mV. Stability testing confirmed that size remained unchanged for up to 4 weeks. For AS1842856, loading was 0.5 mg drug/mL solution and encapsulation efficiency was ~100%. Dialysis indicated burst release of drug in the first 4 hours.

Conclusion: PLGA encapsulation of AS1842856 was successful but unsuccessful for the two more hydrophilic drugs. Alternative syntheses such as water/oil/water emulsion or liposomal encapsulation are being considered. Analysis of data from published papers on PLGA nanoparticles indicated that our results were consistent with identified process-structure relationships and few groups reported endotoxin levels even though in vivo testing was performed.

Publication Date



Social and Behavioral Sciences

Is Part Of

VCU Graduate Research Posters

Development of a targeted and controlled nanoparticle delivery system for FoxO1 inhibitors